Systematic statistical analysis of change in SEIzure interVAL with diazepam nasal spray supports this novel clinical endpoint for immediate‐use seizure medication
Epilepsia · 2026-07 · 67 (7) · 3432-3443
DOI: 10.1002/epi.70222 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Epilepsia, online erschienen am 01.04.2026. Verfasst von Wesley T Kerr und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Epilepsy, Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Anticonvulsants, Diazepam, Epilepsy, Seizures. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, Neurelis, Inc. W.T.K's research time funded by the National Institute of Neurological Disorders and Stroke, Neurelis.
Abstract (Originalsprache)
Objective
Appropriate endpoints for daily antiseizure medications may differ from those for intermittent, immediate‐use seizure medications (ISMs). The observed interval between seizure clusters over time (SEIzure interVAL [SEIVAL]) has been proposed as a novel effectiveness endpoint for ISMs. SEIVAL was initially identified pragmatically. This post hoc analysis evaluated how the study timeline and participant characteristics could impact the measurement of SEIVAL using data from an open‐label study of intermittent treatment with diazepam nasal spray.
Methods
This analysis includes data from a long‐term, phase 3 safety study of diazepam nasal spray, which enrolled patients aged 6–65 years with epilepsy and seizure clusters (NCT02721069). Study timeline and participant characteristic choices were evaluated systematically to determine the impact on effect size, and thereby statistical power, using data regarding individual treated seizure clusters. In this strategy, the date of the first treated seizure cluster constituted day 1 of the baseline period; consecutive 70‐day periods were used for analysis. The change in SEIVAL for each patient was calculated using each measured SEIVAL for that patient in the primary outcome period (days 71–140) minus that patient's mean SEIVAL in the baseline period (days 1–70) with mixed effects linear regression.
Results
Mean SEIVAL increased from 13 days at baseline (days 1–70) to 24 days in the primary outcome period (days 71–140, p < .0001). SEIVAL lengthening was seen in adults, adolescents (ages 6–17 years), and children (ages 6–12 years), with further lengthening past 140 days in adolescents and children. SEIVAL lengthened more in participants with
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Epilepsy, Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Neurelis, San Diego, California, USA.
- John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, USA.
- Center for Molecular Biology and Biotechnology, Charles E. Schmidt College of Science, Florida Atlantic University, Boca Raton, Florida, USA.
ORCID-Profile: Wesley T Kerr, Katherine N McFarlane, Leock Y Ngo, Enrique Carrazana, Adrian L Rabinowicz
Förderung
- NINDS NIH HHS
- Neurelis, Inc. W.T.K's research time funded by the National Institute of Neurological Disorders and Stroke
- Neurelis
Zitieren
APA
Kerr, W. T., McFarlane, K. N., Ngo, L. Y., Carrazana, E., & Rabinowicz, A. L. (2026). Systematic statistical analysis of change in SEIzure interVAL with diazepam nasal spray supports this novel clinical endpoint for immediate‐use seizure medication. Epilepsia, 67(7), 3432-3443. https://doi.org/10.1002/epi.70222
Vancouver
Kerr WT, McFarlane KN, Ngo LY, Carrazana E, Rabinowicz AL. Systematic statistical analysis of change in SEIzure interVAL with diazepam nasal spray supports this novel clinical endpoint for immediate‐use seizure medication. Epilepsia. 2026;67(7):3432-3443. doi:10.1002/epi.70222
BibTeX
@article{Kerr2026,
author = {Kerr, Wesley T and McFarlane, Katherine N and Ngo, Leock Y and Carrazana, Enrique and Rabinowicz, Adrian L},
title = {Systematic statistical analysis of change in SEIzure interVAL with diazepam nasal spray supports this novel clinical endpoint for immediate‐use seizure medication},
journal = {Epilepsia},
year = {2026},
volume = {67},
number = {7},
pages = {3432--3443},
doi = {10.1002/epi.70222}
}
EUVIMED